MX2016000884A - Composicion para la gestion de las nauseas y los vomitos. - Google Patents

Composicion para la gestion de las nauseas y los vomitos.

Info

Publication number
MX2016000884A
MX2016000884A MX2016000884A MX2016000884A MX2016000884A MX 2016000884 A MX2016000884 A MX 2016000884A MX 2016000884 A MX2016000884 A MX 2016000884A MX 2016000884 A MX2016000884 A MX 2016000884A MX 2016000884 A MX2016000884 A MX 2016000884A
Authority
MX
Mexico
Prior art keywords
nausea
vomiting
effective amount
management
composition
Prior art date
Application number
MX2016000884A
Other languages
English (en)
Other versions
MX366760B (es
Inventor
Manon Vranderick
Michele Gallo
Éric Gervais
Jean-Luc St-Onge
Original Assignee
Duchesnay Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50877783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016000884(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duchesnay Inc filed Critical Duchesnay Inc
Publication of MX2016000884A publication Critical patent/MX2016000884A/es
Publication of MX366760B publication Critical patent/MX366760B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Sistema de dosificación farmacéutica que comprende (a) una cantidad eficaz de uno o más de los siguientes ingredientes: (i) la doxilamina, (ii) un análogo de la doxilamina, (iii) un derivado de la doxilamina, (iv) una prodroga de la doxilamina, (v) un metabolito de la doxilamina o (vi) una sal farmacéuticamente aceptable de cualquiera de los ingredientes (i) a (v); (b) una cantidad eficaz de uno o más de los siguientes ingredientes: (i) la piridoxina, (ii) un análogo de la piridoxina, (iii) un derivado de la piridoxina, (iv) una prodroga de la piridoxina, (v) un metabolito de la piridoxina o (vi) una sal farmacéuticamente aceptable de cualquiera de los ingredientes (i) a (v); y (c) una cantidad eficaz de uno o más compuestos de fórmula (I) (ver Fórmula) donde R es H, PO3 o Este sistema presenta un perfil farmacocinético superior al de la formulación actual basada en Diclectin(r)/Diclegis(r), y por ejemplo, es útil para aliviar las náuseas y los vómitos, tales como las náuseas y los vómitos durante el embarazo (NVP).
MX2016000884A 2013-07-22 2014-03-13 Composición para la gestión de las náuseas y los vómitos. MX366760B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361856971P 2013-07-22 2013-07-22
PCT/CA2014/050231 WO2015010194A1 (en) 2013-07-22 2014-03-13 Composition for the management of nausea and vomiting

Publications (2)

Publication Number Publication Date
MX2016000884A true MX2016000884A (es) 2016-05-05
MX366760B MX366760B (es) 2019-07-23

Family

ID=50877783

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000884A MX366760B (es) 2013-07-22 2014-03-13 Composición para la gestión de las náuseas y los vómitos.

Country Status (29)

Country Link
US (1) US10028941B2 (es)
EP (1) EP3024466B1 (es)
JP (1) JP6379194B2 (es)
KR (1) KR102242391B1 (es)
CN (1) CN105492013B (es)
AR (1) AR097023A1 (es)
AU (1) AU2014295765B2 (es)
BR (1) BR112016001474A2 (es)
CA (1) CA2847022C (es)
CL (1) CL2016000154A1 (es)
CY (1) CY1120386T1 (es)
DK (1) DK3024466T3 (es)
EA (1) EA029690B1 (es)
ES (1) ES2670619T3 (es)
HK (1) HK1218264A1 (es)
HU (1) HUE039131T2 (es)
IL (1) IL243638B (es)
MX (1) MX366760B (es)
MY (1) MY191347A (es)
NO (1) NO3086669T3 (es)
NZ (1) NZ716017A (es)
PL (1) PL3024466T3 (es)
PT (1) PT3024466T (es)
SA (1) SA516370443B1 (es)
SG (1) SG11201600122RA (es)
TW (2) TWI589292B (es)
UY (1) UY35674A (es)
WO (1) WO2015010194A1 (es)
ZA (1) ZA201600383B (es)

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
GB8524001D0 (en) 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
US4842867A (en) 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
IT1201136B (it) 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
US5110597A (en) 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5387421A (en) 1991-01-31 1995-02-07 Tsrl, Inc. Multi stage drug delivery system
NZ286242A (en) 1991-03-26 1997-11-24 Csl Ltd Use of veterinary implant as a single dose vaccination system: rupturable polymer film coating around core of active agent and water soluble excipient
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
DE19716732C2 (de) 1997-03-07 1999-03-25 Max Delbrueck Centrum Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US7744916B2 (en) 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
AU4221300A (en) 1999-04-06 2000-10-23 Kamal K. Midha Pharmaceutical dosage form for pulsatile delivery of (d-threo)-methylphenidate and a second cns stimulant
US6197329B1 (en) * 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
AU4305101A (en) 1999-11-22 2001-06-04 Research Foundation Of The State University Of New York, The Magnetic nanoparticles for selective therapy
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US6924273B2 (en) 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
CA2350195C (en) * 2000-12-20 2003-06-10 Duchesnay Inc. Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate
WO2002055058A2 (en) 2001-01-09 2002-07-18 Microchips, Inc. Flexible microchip devices for ophthalmic and other applications
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7704542B2 (en) * 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
WO2004071487A2 (en) 2002-08-16 2004-08-26 Microchips, Inc. Controlled release device and method
GB0229725D0 (en) 2002-12-19 2003-01-29 Univ Wales Medicine Haplotype partitioning and growth hormone SNPs
US20100221321A1 (en) 2003-02-27 2010-09-02 Innercap Technologies, Inc. Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions
EP1791643B1 (en) 2004-09-01 2009-03-11 Microchips, Inc. Multi-cap reservoir devices for controlled release or exposure of reservoir contents
GB0502475D0 (en) 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070141147A1 (en) 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
KR101190708B1 (ko) 2010-03-12 2012-10-12 주식회사 대웅제약 모사프리드 또는 이의 염을 포함하는 서방형 약학 조성물
US9884022B2 (en) 2010-04-07 2018-02-06 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
CA2802335A1 (en) 2010-06-22 2011-12-29 Twi Pharmaceuticals, Inc. Controlled release compositions with reduced food effect
US9421171B2 (en) 2011-02-14 2016-08-23 The Procter & Gamble Company Coated solid dosage forms
EP2717860A4 (en) 2011-06-08 2014-11-05 Sti Pharma Llc FORMULATION FROM A WATER SOLUBLE AND PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND WITH CONTROLLED ABSORPTION FOR ONLY DAILY APPLICATION
WO2013123569A1 (en) 2012-02-22 2013-08-29 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
PL3326611T3 (pl) 2012-02-22 2020-11-02 Duchesnay Inc. Formulacja doksylaminy i piiridoksyny i/lub ich metabolitów lub ich soli
US9452181B2 (en) 2013-07-22 2016-09-27 Duchesnay Inc. Composition for the management of nausea and vomiting

Also Published As

Publication number Publication date
SG11201600122RA (en) 2016-02-26
IL243638B (en) 2019-09-26
CA2847022A1 (en) 2014-06-03
HUE039131T2 (hu) 2018-12-28
UY35674A (es) 2014-12-31
MX366760B (es) 2019-07-23
CA2847022C (en) 2015-04-07
EP3024466A1 (en) 2016-06-01
TW201513860A (zh) 2015-04-16
BR112016001474A2 (pt) 2020-04-14
EA029690B1 (ru) 2018-04-30
TW201720442A (zh) 2017-06-16
TWI589292B (zh) 2017-07-01
WO2015010194A1 (en) 2015-01-29
PT3024466T (pt) 2018-07-13
TWI654977B (zh) 2019-04-01
KR20160033201A (ko) 2016-03-25
US20160143892A1 (en) 2016-05-26
PL3024466T3 (pl) 2018-08-31
EP3024466A4 (en) 2017-03-29
JP2016527237A (ja) 2016-09-08
HK1218264A1 (zh) 2017-02-10
EA201690149A1 (ru) 2016-06-30
CL2016000154A1 (es) 2016-08-05
AR097023A1 (es) 2016-02-10
US10028941B2 (en) 2018-07-24
IL243638A0 (en) 2016-02-29
CN105492013A (zh) 2016-04-13
JP6379194B2 (ja) 2018-08-22
DK3024466T3 (en) 2018-06-06
NO3086669T3 (es) 2018-06-23
CN105492013B (zh) 2018-09-18
CY1120386T1 (el) 2019-07-10
AU2014295765A1 (en) 2016-02-04
AU2014295765B2 (en) 2019-02-14
SA516370443B1 (ar) 2018-08-08
MY191347A (en) 2022-06-17
EP3024466B1 (en) 2018-04-04
ES2670619T3 (es) 2018-05-31
NZ716017A (en) 2020-07-31
KR102242391B1 (ko) 2021-04-21
ZA201600383B (en) 2017-11-29

Similar Documents

Publication Publication Date Title
PH12016500072A1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
MX2014008594A (es) Formulacion de doxilamina y piridoxina y/o sus metabolitos o sales.
EP3040072A4 (en) Pharmaceutical composition having pyrimidine compound as active ingredient
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
GEP201706748B (en) Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
MD20140072A2 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
MX2019009100A (es) Nuevos derivados de triazolo[4,5-d]pirimidina.
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
PH12015502409A1 (en) Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
CA2904820C (en) Pyridinylpyrazoloquinoline compound
PH12016500134A1 (en) 1-(piperazin-1-yl) -2- ([1,2,4] triazol -1- yl) - ethanone derivatives
PH12015501701A1 (en) Formulation comprising benzothiazolone compound
MX2016000884A (es) Composicion para la gestion de las nauseas y los vomitos.
MX2016000775A (es) Preparacion farmaceutica que comprende un derivado de aminopirazol.
RU2012152490A (ru) Способ фармакологической коррекции ишемии скелетной мышцы ресвератролом
CA2905957C (en) Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders
IN2013MU03656A (es)
IN2013DE00880A (es)

Legal Events

Date Code Title Description
FG Grant or registration